Anti-Myeloma Effects of Panobinostat in Combination with Duvelisib
Blood, 2021 Abstract Introduction: Panobinostat (Secura Bio) is a non-selective histone deacetylase inhibitor (HDACi) that has shown anti-tumor activity in preclinical studies in both solid and hematological malignancies. Duvelisib (Secura Bio) is an FDA-approved oral drug and a potent small molecule inhibitor of the delta (δ) and gamma (γ) isoforms
Haiming Chen +10 more
openaire +1 more source
Interleukin-6 mediates resistance to PI3K-pathway–targeted therapy in lymphoma
BMC Cancer, 2019 Background The phosphoinositol 3-kinase (PI3K) pathway is associated with poor prognosis of hematologic malignancies, providing a strong rationale for the use of PI3K inhibitors in the treatment of malignant lymphoma.
Joo Hyun Kim, Won Seog Kim, Chaehwa Park
doaj +1 more source
Targeting Brutons Tyrosine Kinase in Chronic Lymphocytic Leukemia at the Crossroad between Intrinsic and Extrinsic Pro-survival Signals [PDF]
, 2016 Chemo immunotherapies for chronic lymphocytic leukemia (CLL) showed a positive impact on clinical outcome, but many patients relapsed or become refractory to the available treatments.
Facco, Monica +7 more
core +1 more source
Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma [PDF]
Blood, 2019 In this Blood Spotlight, the authors review the appropriate clinical background, mechanism of action, and detailed therapeutic data about duvelisib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma.
Krish, Patel +2 more
openaire +2 more sources
Drug-perturbation-based stratification of blood cancer [PDF]
, 2018 As new generations of targeted therapies emerge and tumor genome sequencing discovers increasingly comprehensive mutation repertoires, the functional relationships of mutations to tumor phenotypes remain largely unknown.
Dietrich, Sascha +3 more
core +1 more source
The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma [PDF]
, 2017 Despite the development of novel treatments in the past 15 years, many blood cancers still remain ultimately fatal and difficult to treat, particularly acute myeloid leukaemia (AML) and multiple myeloma (MM).
Bowles, Kristian M. +2 more
core +1 more source
PLoS ONE, 2018 Duvelisib is an orally active dual inhibitor of PI3K-δ and PI3K-γ in clinical development in hematologic malignancies (HM). To identify novel pairings for duvelisib in HM, it was evaluated alone and in combination with 35 compounds comprising a diverse ...
Kerrie Faia +7 more
doaj +1 more source
CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies [PDF]
, 2016 Expression of CD20 antigen by the most of transformed B cells is believed to be the driving force for targeting this molecule by using anti-CD20 monoclonal antibodies. While it is true that most lymphoma/leukemia patients can be cured, these regimens are
Ahmadzadeh, V. +2 more
core +1 more source
Neuroscience Insights, 2023 Epilepsy is one of the most common neurological diseases, which is caused by abnormal brain activity. A wide variety of studies have shown the importance of the phosphatidylinositol-3-kinase (PI3K) signaling pathway in epilepsy pathogenesis.
Mahnaz Abdolrahmani +2 more
doaj +1 more source
Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update [PDF]
, 2018 Despite considerable progress in treatment protocols, B-lineage acute lymphoblastic leukemia (B-ALL) displays a poor prognosis in about 15–20% of pediatric cases and about 60% of adult patients. In addition, life-long irreversible late effects from chemo-
Capitani, Silvano +6 more
core +1 more source